Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | ALPL | P05186 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5267166 | 0.88 | NPC1 (0.52) | ALDH1A1NPC1RAB9ATSHRMAPK10 | |
| SCHEMBL5267582 | 0.85 | LMNA (0.56) | ALDH1A1NPC1RAB9ATSHRMAPK10 | |
| SCHEMBL5269224 | 0.82 | KDM4E (0.49) | ALDH1A1NPC1RAB9AGAASMN1; SMN2 | |
| SCHEMBL5270571 | 0.82 | KMT2A (0.59) | ALDH1A1NPC1RAB9ATSHRMAPK10 | |
| SCHEMBL5269233 | 0.81 | KMT2A (0.51) | ALDH1A1NPC1RAB9ATSHRL3MBTL1 | |
| SCHEMBL5267481 | 0.81 | MDM4 (0.49) | ALDH1A1NPC1RAB9AGAASMN1; SMN2 | |
| SCHEMBL5265952 | 0.80 | KMT2A (0.52) | ALDH1A1NPC1RAB9AL3MBTL1GAA | |
| SCHEMBL5266469 | 0.80 | SMN1; SMN2 (0.56) | ALDH1A1NPC1RAB9AL3MBTL1GAA | |
| SCHEMBL5270659 | 0.80 | KDM4E (0.44) | ALDH1A1RAB9ATSHRHSD17B10SMN1; SMN2 | |
| SCHEMBL5271746 | 0.80 | ALDH1A1 (0.50) | ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156582-A1 | Pyrazole Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-1847531-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156582-A1 | Pyrazole Compound | GSK3B, GSK3A, GSKIP | ALDH1A1 694/4885NPC1 1266/4885RAB9A 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.